tbuckley/cabot-search huggingface dataset:
Policies for Posting Biomedical Journal Information on the Internet
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcomes of cancer patients treated with drotrecogin alfa (activated) for severe sepsis
Authors: D. Joyce, J. Leclerc, D. Nelson, H. Levy, R. Garg
Journal: Journal of Clinical Oncology (2004)

6055 Background: Drotrecogin alfa (activated) (Xigris®; DAA), was approved for the treatment of severe sepsis in many countries based on a pivotal phase 3 trial of 1690 patients. DAA, has antithrombotic, profibrinolytic and anti-inflammatory properties and may improve microvascular thrombosis to reduce organ dysfunction in sepsis. We are reporting 1-month mortality outcomes among 303 patients with any prior or current history of malignancy enrolled in this pivotal trial (PROWESS). Methods: A post-hoc subgroup analysis was preformed on the 303 PROWESS cancer patients with acute sepsis-related organ dysfunction and who received standard therapy and either DAA at 24ug/kg/hr or placebo for 96 hrs. Patients were excluded for increased bleeding risk, including platelet count<30K/mm3, history of bone marrow transplant, poorly controlled neoplasm, or likely death from a non-sepsis cause within 28-days. Mortality and bleeding were evaluated at the 28-day PROWESS endpoint and mortality at 1-year. Results: Compared to the entire cohort cancer patients were older, had more chronic health points, and higher APACHE II scores. Cancer patients had a lower survival rate than the overall PROWESS group. Cancer patients experienced a significant treatment effect (28-day relative risk: 0.68) similar to the overall trial population (RR: 0.80). This benefit was similar at one year. Cancer and PROWESS patients experienced a similar rate of serious adverse bleeding events. Conclusions: CONCLUSION: DAA is efficacious and safe in patients with severe sepsis and early stage cancer or a history of malignancy. Despite increased baseline morbidity, DAA produced an increase in 28-day survival in cancer patients that was similar to the overall trial population. This treatment effect appeared to persist over the first year following the severe sepsis episode. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly & Co. Eli Lilly & Co.
Variant angina pectoris. Pain and arrhythmias controlled after postoperative myocardial infarction
Authors: C. A. Marsh
Journal: JAMA (1976)

A 30-year-old man with variant angina pectoris and ventricular arrhythmias had an angiographically demonstrable 60% obstructive lesion of the proximal left anterior descending coronary artery that was observed to progress to 100% during spasm. Control of pain and arrhythmia by pharmacologic means was unsuccessful. Aortocoronary saphenous vein-internal mammary coronary bypass was associated with an anteroseptal wall myocardial infarction and relief from both angina pectoris and arrhythmias. It is suggested that infarction of the ischemic myocardium played a role in the successful management of this case. (<i>JAMA</i>235:833-837, 1976)
Efficacy of vemurafenib (V), a selective <sup>V600E</sup>b-raf inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.
Authors: B. Higgins, K. D. Kolinsky, K. Schostack, G. Bollag, R. J. Lee, D. C. Heimbrook, F. Su, K. Packman
Journal: Journal of Clinical Oncology (2011)

e13554 Background: B-Raf mutations, particularly at V600E occur in 8%-30% of CRCs resulting in constitutive activation of the MEK-ERK pathway. V is a first-in-class, V600EB-Raf-selective small molecule inhibitor previously shown to potentiate anti-tumor effects in the V600E CRC xenograft model HT29 in combination (combo) with capecitabine ± bevacizumab (ASCO GI, 2008). V600E CRC respond poorly to EGFR inhibition (EGFRi) both preclinically and clinically. We aimed to determine whether antitumor activity could be potentiated by combining V with EGFRi. Methods: The monotherapy (mono) activities of V, Erl, Erb and Iri were compared to combo of these agents in the HT29 model. V was tested as a mono at its optimal dose (OD), and Erl was tested at its MTD or 2/3 MTD, or a combo of V OD + 2/3 MTD Erl. V was subsequently tested as mono or combo at the OD and suboptimal-OD with OD Erb. A final study included Iri as mono, doublets of Iri + V or Erb, and triplet combo of Iri, V, and Erb. Results: The tumor growth inhibition (TGI) and increase in life span (ILS) for combo of OD V + 2/3 MTD Erl was superior to all mono arms. TGI in mono arms was equivalent for V, Erb and Iri. ILS was better for V vs Iri and Erb mono, while Iri vs Erb ILS were equivalent. TGI and ILS for Iri + Erb doublet was equivalent to V mono. Otherwise, TGI and ILS in all other doublets and triplets were superior to mono groups. TGI in V + Erb and V + Iri were equivalent, but ILS was better for V + Iri. TGI and ILS for V + Iri was better than Iri + Erb. TGI in V + Erb was better than Iri + Erb, but ILS was equivalent. TGI in the triplet was superior to all doublets except V + Erb, however ILS was superior to all doublets tested. Conclusions: V potentiates anti-tumor activity in a V600E CRC model when used in combo with Erl, Erb and Iri. Although a V + Erb doublet provided impressive TGI equivalent to a triplet with Iri, the triplet yielded sustained antitumor activity as demonstrated by a significant increase in survival as compared to the doublet. Combo with V may afford V600E CRC patients a differential response to what is seen traditionally with single agent EGFi and is worthy of clinical exploration.
LIVER AND PLASMA PROTEIN SYNTHESIS
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fiscal Responsibility and Health Care Reform
Authors: R. A. Levine
Journal: New England Journal of Medicine (2009)

It has been clear for some time that the primary hurdle to enacting health care reform is figuring out how to pay for it. Virtually all Republicans and some Democrats have been unwilling to sign on to increasing taxes on high-income Americans as a partial answer. The idea of taxing the most generous health insurance benefits has met with resistance as well. The use of electronic health records and an emphasis on prevention and early treatment of illnesses have been ballyhooed as ways to generate savings to help pay for reform, but there is no solid evidence that these measures . . .
Adolescents as victims of family violence. Council on Scientific Affairs, American Medical Association
Journal: JAMA (1993)

Adolescents experience maltreatment at rates equal to or exceeding those of younger children. Recent increases in reported cases of maltreatment have occurred disproportionately among older children and adolescents. However, adolescents are less likely to be reported to child protective services and are more likely to be perceived as responsible for their maltreatment. Adolescent girls are reported as victims more often than boys, especially in sexual abuse. However, boys may be less likely to be identified or reported and often are abused by nonfamily members. Parents of adolescent victims have higher average income and educational levels and are less likely to have a parental history of abuse than parents of younger children. A wide range of serious adolescent risk behaviors is associated with maltreatment. These include increased risk of premature sexual activity, unintended pregnancy, emotional disorders, suicide attempts, eating disorders, alcohol and other drug abuse, and delinquent behavior. Incarcerated youth, homeless or runaway youth, and youth who victimize siblings or assault parents have been shown to have high rates of prior maltreatment. Signs of maltreatment are often ambiguous for adolescents. Screening questions have been effective in prompting self-disclosure of abuse. Adolescents also experience problems in the child welfare system that offers fewer and less appropriate services for this age group. Recommendations are made regarding screening of adolescents for maltreatment, the development of better services for adolescents, research on parenting to prevent maltreatment, and training of school staff to identify and refer victims of maltreatment.
Antepartum Evaluation of the High-Risk Fetus: Problems and Prospects
Authors: S. Fabro
Journal: Environmental Health Perspectives (1976)

The chief obstetrical problems encountered today in the prenatal evaluation of the high-risk fetus are presented. Advantages and pitfalls or recent techniques utilized in the management of the high-risk pregnancy are discussed. They include: a prenatal scoring system for identifying the high-risk population; examination of the karyotype of cells in amniotic fluid, and quantitation of alpha-fetoprotein levels in maternal plasma and amniotic fluid for the early prenatal detection of birth defects; ultrasonography for the intrauterine diagnosis of fetal growth retardation and assessment of fetal maturity; the use of maternal urinary estriol excretion, maternal plasma human placental lactogen levels and the oxytocin stress test for the early detection of fetal distress; estimation of fetal maturity by amniotic fluid analysis of lecithin or lecithin-sphingomyelin ratios, creatinine and Blue Nile fetal cell staining. Newer, still experimental, techniques (e.g., fatal breathing movements, fetoscopy, and dehydroepiandrosterone plasma clearance) are viewed in light of further possible decreases in maternal and perinatal mortality.
THE DREYER TUBERCULOSIS VACCINE
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE REPORT OF THE BRITISH VACCINATION COMMISSION.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hematological reactions
Authors: C. M. Huguley
Journal: JAMA (1966)

The blood dyscrasias that may follow the use of drugs are aplastic anemia, erythroid hypoplasia without pancytopenia, leukopenia and agranulocytosis, thrombocytopenia, hemolytic anemia, and megaloblastic anemia. The most important of these are aplastic anemia and agranulocytosis, both because of their frequency of occurrence and their high fatality rates. <h3>Blood Dyscrasias</h3><h3>Aplastic Anemia.—</h3> The mechanism by which drugs produce aplastic anemia is not known. Indeed, the evidence that any drug may produce aplastic anemia is largely circumstantial. Many patients in whom aplastic anemia develops are not aware that they had taken any drugs and, even when drugs had been taken, there is not necessarily an etiological relationship to the anemia. Nevertheless, the circumstantial evidence against some drugs, particularly chloramphenicol, is overwhelming. Of about 700 cases of aplastic anemia reported to the AMA Registry on Blood Dyscrasias in a seven-year period, 45% of the patients had received chloramphenicol; 20% of these patients
Benzene and Leukemia: An Epidemiologic Risk Assessment
Authors: Robert A. Rinsky
Journal: Environmental Health Perspectives (1989)

To assess quantitatively the association between benzene and leukemia, we evaluated the rate of mortality experienced by a cohort occupationally exposed to benzene. Using data from historical air sampling surveys, we estimated the daily benzene exposure for each member of the cohort. The expected number of leukemia deaths was calculated and compared to the actual number of leukemia deaths that occurred. The overall standardized mortality ratio (SMR) for leukemia was 337. Person-years at risk within the cohort were stratified by increasing levels of cumulative benzene exposure. The resulting SMRs increased from 109 to 322 to 1186 and to 6637 with respective increases in cumulative benzene exposure from less than 40 ppm-years to 40-199, 200-399, and greater than 400. The shape of the exposure-response relation was examined with a case-control analysis. Another analysis was performed to take into account an induction period for leukemia. All of the analyses demonstrated that a strongly positive exposure-response relationship exists between benzene and leukemia. Previous attempts to quantify this cohort's risk of developing leukemia were based on surrogates of exposure, such as duration of employment. Using actual air sampling data to estimate individual exposures represents a marked improvement over these previous attempts and emphasizes the importance of conducting industrial hygiene surveys and maintaining historical exposure records.
Viral Hepatitis Associated With Sub-Human Primates
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characteristics of Women Receiving Family Planning Services at Title X Clinics— United States, 1991
Journal: JAMA (1994)

In 1970, enactment of federal legislation created a national family planning program funded under Title X of the Public Health Services Act. Since the enactment of this legislation, clinics funded entirely or partially by Title X have been the primary source of subsidized family planning services in the United States. Although information characterizing women who receive family planning services at Title X clinics can assist in program planning and operations, such information has not been compiled at the national level since 1981. In 1992, state family planning administrators and CDC, with cooperation from Title X grantees, initiated the Family Planning Services Surveillance (FPSS) project to characterize women receiving family planning services from Title X clinics in 1991. This report presents the findings of FPSS.
Green Turtle Fibropapillomatosis: Challenges to Assessing the Role of Environmental Cofactors
Authors: Lawrence H. Herbst, Paul A. Klein
Journal: Environmental Health Perspectives (1995)

Green turtle fibropapillomatosis (GTFP) is a growing threat to the survival of green turtle (Chelonia mydas) populations worldwide.Recent transmis- sion studies point to an infectious etiology.Several field studies suggest that high GTFP prevalence is associated with marine habitats that have been impacted by agricultural, industrial, or urban development.Environmental contaminants could be involved in GTFP through several plausible mechanisms including cocarcinogenesis and contaminant-induced immune suppression.However, an association of contaminants with GTFP has not been established.A broader perspective is needed when studying infectious diseases such as GTFP in complex ecosystems.Alternative expla- nations for high GTFP prevalence in some near-shore habitats include the following: a) these habitats provide an optimum physical environment for survival and transmission of the infectious agent; b) these habitats attract a high density of susceptible turtles or harbor a higher density of potential vectors, facilitating transmission of the pathogen in a density-dependent fashion; and c) these habitats may contain other stressors that render turtles more susceptible to GTFP.Application of scientifically rigorous criteria in the epizootiology of GTFP in free-ranging populations remains a formidable challenge.
Radical approaches: is widespread testing and treatment for oxidative injuries coming soon?
Authors: R. Voelker
Journal: JAMA (1993)

FREE RADICALS are overtaking more than the lipids, proteins, and DNA contained in human cells. Just a few years ago, these molecular Jack the Rippers were largely the purview of chemists and biochemists. But now that their expansive role in human disease is being acknowledged in clinical medicine, research scientists and physicians are clamoring to know more. How can their presence in the body be detected? Once their destructive reactions begin, can they be stopped? Once their damage has been done, can it be repaired? Is the havoc they wreak preventable? When will widespread diagnosis and treatment become available? Some of the answers have yet to be determined. Emerging data and theories were discussed recently in Buffalo, NY, at the first international symposium on the topic, Free Radicals in Diagnostic Medicine: A Systems Approach to Laboratory Technology, Clinical Correlations, and Antioxidant Therapy. The meeting was sponsored by the State University
Heberden Society: Annual Report, 1950
Authors: J Kellgren's Depart-
Journal: Annals of the Rheumatic Diseases (1951)

The Society has had a successful year of work.The membership is now at the maxi- mum of 100, two members having resigned and nine applicants having been admitted during the year, and there is still a waiting list for membership.The new Honorary Members are Professor Hans Selye and Professor F. Coste, who respectively gave the Heberden Oration and the Heberden Round.The first meeting was held at the Westminster Hospital on January 6, 1950.The members were
Liver involvement in patients with telomere-related genes mutations: prevalence, clinical, radiological, pathological features, outcome and risk factors
Authors: Sabrina Sidali, Raphaël Borie, Sicre Flore, Elodie Lainey, Pierre-Emmanuel Rautou, Jacques Cadranel, Jean-marc Naccache, Vincent Cottin, Jérôme Dumortier, Emmanuel Jacquemin, Nousbaum Jean Baptiste, Sandrine Hirschi, Arnaud Bourdin, Magdalena Meszaros, Sebastien Dharancy, Sophie Hilaire, Vincent Mallet, Reynaud-Gaubert Martine, Louis Terriou, Frédéric Gottrand, Wadih Abou Chahla, Jean Emmanuel Khan, Paul Carrier, Faouzi Saliba, Laura Rubbia-Brandt, Laure Elkrief, Victor de Lédinghen, Armand Abergel, Tournilhac Olivier, Yasmina Chouik, Antoine Coupier, Thierry Leblanc, Isabelle Ollivier-Hourmand, Eric Nguyen Khac, Hélène Morisse-Pradier, Kinan El Husseini, Odile Goria, Ba Ibrahima, Dominique Roulot, Christophe Bureau, Hilario Nunes, Dominique Valla, Valérie Paradis, Kannengiesser Caroline, Aurélie Plessier
Journal: Journal of Hepatology (2020)